First Patient Dosed in Prime Medicine's Wilson Disease Trial; Shares Jump 21%
PRME sits 93% above its 52-week low of $2.67 on elevated volume (2.8× avg).
Summary
Prime Medicine dosed the first patient in a Phase 1/2 trial of PM577a, an in vivo prime editor for H1069Q-mutated Wilson disease — the first clinical evaluation of its liver franchise. The FDA also granted rare pediatric disease designation to PM577 for Wilson disease, which opens the door to a priority review voucher if approved. Shares rose 21% to $5.27, just off a 52-week high. The trial is open-label and first-in-human, starting with adults stable on standard-of-care therapy before expanding to adolescents. This is a genuine clinical milestone for a company under a going concern warning with $95.1 million in cash as of the Q2 10-Q — progress on the pipeline is what keeps the story alive while it needs to raise capital. The rare pediatric designation adds a potential non-dilutive value lever.
At the time of this announcement, PRME was trading at $5.16 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $935.9M. The 52-week trading range was $2.67 to $5.29. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.